肠致病性大肠杆菌O45基因缺失疫苗菌株的构建及其免疫原性分析

为得到肠致病性大肠杆菌O45弱毒疫苗候选菌株，以肠致病性大肠杆菌O45为出发菌株, 利用自杀性载体pCVD442和同源重组的原理构建了O45的ler基因缺失突变菌株PEPEC O45(Δler), 并对该菌株的Vero细胞毒性、小鼠模型的安全性以及乳鼠和乳猪的被动免疫保护作用进行了研究。结果表明, O45(Δler)基因缺失突变菌株丧失了对Vero细胞的毒性作用, 并丧失了对实验小鼠的致病性, 具有良好的安全性。乳鼠和乳猪被动免疫保护性实验表明, 用该菌株分别免疫母鼠和母猪后, 乳鼠和乳猪均可通过吸吮母乳可以获得良好的被动免疫保护作用。因此本研究所构建的O45(Δler)基因缺失突变弱毒菌株可作为预防PEPEC O45感染的疫苗候选株, 为最终研制出O45的基因工程菌苗奠定基础。

Construction and immunization of an attenuated vaccine candidate enteropathogenic Escherichia coli O45

In order to obtain an attenuated vaccine candidate for enteropathogenic Escherichia coli (EPEC) O45, a ler deletion mutant of pig enteropathogenic E. coli (PEPEC) O45 was constructed by using the suicide vector pCVD442, termed as PEPEC O45(Dler). The culture supernatant of PEPEC O45(Dler) deletion mutant was inoculated in vero cell culture. PEPEC O45(Dler) deletion mutant lost the toxigenicity to vero cell. Test group and control group of mice were orogstrically inoculated with the PEPEC O45(Dler) deletion mutant and the virulent strain O45 respectively. Mice were observed daily for clinical signs and weight changes. Test group of mice inoculated with PEPEC O45(Dler) gained weight normally and experienced no clinical signs. In contrast, control group of mice inoculated with virulent strain O45 exhibited weight loss and all died in four days. In another experiment, pregnant mice and pig were orally vaccinated by PEPEC O45(Dler) twice at interval of 14 days respectively. Subsequently, the suckling mice and pig were orally challenged with O45 at 7 days of age respectively. The results showed that 80% of the sucking mice born by vaccinated mice and 75% of the sucking pig born by vaccinated pig were survival; 15% of the sucking mice born by non-vaccinated mice and 10% of the sucking pig born by non-vaccinated pig were survival. This study demonstrated that PEPEC O45(Dler) deletion mutant lost the toxigenicity to vero cell and to be safety to mice and pig. Oral immunization can induce specific immune responses in mice and pig, and this mutant strain could be used as an attenuated vaccine candidate against PEPEC O45.